Novartis Hid Manipulated Data While Seeking Approval for $2.1 Million Treatment
The failure to report the issue has not put patients at risk, the F.D.A. said, but the drugmaker could face criminal and civil penalties.
Source: NYT Health - Category: Consumer Health News Authors: Katie Thomas Tags: Novartis AG Food and Drug Administration Drugs (Pharmaceuticals) Spinal Muscular Atrophy Genetics and Heredity gene therapy your-feed-healthcare Source Type: news
More News: Food and Drug Administration (FDA) | Gene Therapy | Genetics | Health | Spinal Muscular Atrophy